皮下注射小剂量地西他滨联合CHAG预激方案治疗17例复发难治性或老年急性髓系白血病患者的疗效分析

刘志娟; 尹青松; 李梦娟; 袁芳芳; 陈琳; 米瑞华; 王倩; 魏旭东

doi:10.13201/j.issn.1004-2806.2019.05.011

皮下注射小剂量地西他滨联合CHAG预激方案治疗17例复发难治性或老年急性髓系白血病患者的疗效分析

- 郑州大学附属肿瘤医院血液科, 河南省肿瘤医院, 河南省血液病研究所(郑州, 450008)
基金项目:
河南省医学科技攻关计划项目（省部共建）（No：201701028）；河南省自然科学基金（No：22180003）

详细信息

通讯作者: 尹青松,E-mail:jnyinqingsong@163.com

中图分类号: R733.71

收稿日期: 2019-02-15

The clinical efficacy and safety of low dose subcutaneous decitabine plus CHAG priming regimen in 17 patients with elderly or relapsed refractory acute myeloid leukemia

- Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, China

More Information

Corresponding author: YIN Qingsong, E-mail: jnyinqingsong@163.com

Received Date: 15 February 2019

摘要

摘要: 目的：观察小剂量地西他滨皮下注射联合CHAG预激方案（D-CHAG）治疗复发难治性或老年急性髓系白血病（AML）患者的疗效和安全性。方法：回顾性分析17例采用D-CHAG预激方案治疗的复发难治性或老年AML患者的临床资料。结果：接受D-CHAG预激方案治疗的17例患者中，14例完全缓解，3例部分缓解，达完全缓解的中位时间为33（24~45） d。14例完全缓解患者中，微小残留病灶阴性10例，包括初治5例，复发难治5例；微小残留病灶阳性4例，其中3例为难治患者，1例为复发患者。主要不良反应为骨髓抑制及感染，无治疗相关死亡发生。结论：对于老年或复发难治性AML患者，D-CHAG预激方案治疗安全、有效。
- 小剂量地西他滨 /
- 皮下注射 /
- 急性髓系白血病 /
- 复发难治 /
- 老年
Abstract: Objective: To observe the efficacy and safety of low-dose subcutaneous decitabine plus CHAG (D-CHAG) priming regimen in patients with elderly or relapsed refractory acute myeloid leukemia (AML).Method: Clinical data of 17 patients with relapsed refractory or elderly AML who were treated with D-CHAG priming regimen were analyzed retrospectively.Result: Among the 17 patients who were treated with the D-CHAG priming regimen,14 cases achieved complete response,3 cases achieved partial response,and the median time of patients achieved complete response was 33 (24 to 45) days.Of the 14 patients with complete response,10 cases were negative for MRD,including 5 cases in initial treatment and 5 cases in relapsed refractory;4 cases were positive for MRD,including 3 cases of refractory patients and 1 case of relapsed patients.The main adverse events were myelosuppression and infection,and no treatment-related death occurred.Conclusion: D-CHAG regimen is safe and effective for elderly or relapsed refractory AML patients.
- low-dose decitabine /
- subcutaneous injection /
- acute myeloid leukemia /
- relapsed refractory /
- elderly

HTML全文

参考文献(13)

[1]	Song L X, Xu L, Li X, et al.Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia[J].Ann Hematol, 2012, 91:1879-1886.
[2]	Huang J, Hong M, Zhu Y, et al.Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia[J].Leuk Lymphoma, 2018, 4:1-10.
[3]	杨懿春, 石林, 王建渝, 等.含地西他滨方案治疗老年急性髓系白血病26例疗效分析[J].临床血液学杂志, 2018, 31(5):50-52, 55.
[4]	陆小云, 徐瑞琴.地西他滨联合CAG方案治疗老年急性髓系白血病的临床效果分析[J].临床血液学杂志, 2017, 30(9):697-700.
[5]	Bao Y, Zhao J, Li ZZ.Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia:a prospective cohort study[J].Clin Transl Oncol, 2018, 20:870-880.
[6]	Patel JP, Gönen M, Figueroa ME, et al.Prognostic relevance of integrated genetic profiling in acute myeloid leukemia[J].N Engl J Med, 2012, 366:1079-1089.
[7]	Yi JH, Park S, Kim JH, et al.A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine[J].Oncotarget, 2018, 9:6607-6614.
[8]	Wang L, Jin J.The Mechanisms of synergistically cytotoxicity induced by homoharringtonine and aclarubicin in acute myeloid leukemia cells[J].Blood, 2012, 120:4313.
[9]	Chen L, Yin QS, Mi RH, et al.CHAG priming regimen for relapsed refractory acute myelogenous leukemia:a modified procedure[J].Leuk Lymphoma, 2013, 54:2291-2293.
[10]	Saunthararajah Y, Sekeres M, Advani A, et al.Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes[J].J Clin Invest, 2015, 125:1043-1055.
[11]	Röllig C, Serve H, Hüttmann A, et al.Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML):a multicentre, phase 2, randomised controlled trial[J].Lancet Oncol, 2015, 16:1691-1699.
[12]	Chang E, Ganguly S, Rajkhowa T, et al.The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells[J].Leukemia, 2015, 30:1025-1032.
[13]	Zhang WP, Yang D, Song XM, et al.Allogeneic peripheral blood stem cell transplantation is a promising and safe choice for the treatment of refractory/relapsed acute myelogenous leukemia, even with a higher leukemia burden[J].Biol Blood Marrow Transplan, 2013, 19:653-660.